0000000000354916

AUTHOR

Elizabeth Harris

showing 2 related works from this author

National identity predicts public health support during a global pandemic

2022

Funder: Research Council of Norway through its Centres of Excellence Scheme, FAIR project No 262675

IMAGEHealth BehaviorCOVID-19 ; national identity ; public health ; pandemic ; cross-culturalCollective narcissismSettore SECS-P/02 - Politica Economicahealth behaviorSociologyRA0421 Public health. Hygiene. Preventive MedicineSettore SECS-P/01 - Economia Politicapublic health behaviours COVID-19 collective behaviourPublic health[SHS.SOCIO]Humanities and Social Sciences/SociologySocial IdentificationQ/706/689/477/2811articleSocial identityPublic Health Global Health Social Medicine and Epidemiology[SHS.ECO]Humanities and Social Sciences/Economics and Finance3142 Public health care science environmental and occupational healthVDP::Medisinske Fag: 700::Helsefag: 8005141 SociologySettore SECS-P/03 - Scienza delle Finanze/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingNational identityHumanCross-Cultural ComparisonBF PsychologyScienceCOVID-19 pandemicBFnational narcissismHV Social pathology. Social and public welfare. CriminologyCOVID-19; Cross-Cultural Comparison; Health Behavior; Humans; Leadership; Pandemics; Public Health; SARS-CoV-2; Self Report; Social Identification; Social ConformityHuman development/692/699/255/2514SDG 3 - Good Health and Well-beingSocial ConformityHuman behaviournational identitypolitical ideologyHumansCOLLECTIVE NARCISSISMSOCIAL IDENTITYPandemicsMCCPandemicIDENTIFICATIONSARS-CoV-2COVID-19DAS[SHS.SCIPO]Humanities and Social Sciences/Political scienceCoronavirusMODELLeadershipFolkhälsovetenskap global hälsa socialmedicin och epidemiologiViral infectionIdenficationImageRA Public aspects of medicine[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieHuman medicineSelf ReportRAModel
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct